Neuropathic pain can feel burning, shooting, stabbing, electric or hypersensitive. It can follow nerve injury, diabetes, shingles, surgery, spinal problems, multiple sclerosis, chemotherapy or other conditions. It is often difficult to live with and difficult to treat. That does not mean neuropathic pain automatically qualifies someone for medical cannabis.
The UK guidance picture is careful. NICE has a separate guideline for neuropathic pain medicines, and it does not list medical cannabis as a usual treatment option. NICE’s cannabis-based medicinal products guideline says not to offer several cannabis-based medicines for chronic pain in adults. The NHS medical cannabis page says the pain evidence is not strong enough to recommend medical cannabis for pain relief.
Private specialist assessment can still exist for some patients under UK prescribing rules, but it is a clinical assessment. It depends on the type of nerve pain, treatment history, current medicines, risks, records and whether a specialist prescriber can justify any discussion of an unlicensed cannabis-based medicine.
This article is not medical advice. It cannot decide suitability, access, product form, dose or monitoring. Those decisions sit with a specialist prescriber.
For wider context, read the MCPH patient guide, medical cannabis for chronic pain: what NICE says and medical cannabis and medication interactions.
The short answer
Neuropathic pain is one of the pain areas patients often ask about because standard painkillers may not work well for nerve pain. There is research interest in cannabinoids and neuropathic pain, but UK public guidance remains restrictive. MCPH should not present medical cannabis as a proven or routine nerve-pain treatment.
The practical access question is usually not “do I have neuropathic pain?”. It is whether a specialist can see a clear diagnosis or working diagnosis, a history of relevant treatments already tried, and a safety profile where the possible benefits and risks can be assessed responsibly.
If you are checking the first-step question, the medical cannabis qualifying conditions guide may help you understand whether you may qualify for a specialist assessment. It is not the final clinical decision.
What neuropathic pain means
Neuropathic pain happens when the nervous system itself is damaged or not working normally. It can feel different from pain caused mainly by inflammation or tissue injury. People may describe burning, shooting, stabbing, tingling, pins and needles, numbness or pain from light touch.
Common examples include diabetic nerve pain, post-herpetic neuralgia after shingles, trigeminal neuralgia, nerve-root pain, pain after surgery or injury, and nerve pain linked with other neurological or medical conditions.
This matters because not all long-term pain is neuropathic. If a private specialist is assessing medical cannabis suitability, they may need to understand whether the pain is genuinely neuropathic, mixed, inflammatory, musculoskeletal, chronic primary pain, or something else. The label affects treatment history, risk assessment and realistic expectations.
What standard UK guidance usually tries first
NICE CG173 covers pharmacological management of neuropathic pain in adults in non-specialist settings. It lists medicines such as amitriptyline, duloxetine, gabapentin and pregabalin as initial treatment options, with review and switching if treatment is not tolerated or effective. Some patients may also use topical treatments or be referred to specialist pain services depending on the situation.
The NHS peripheral neuropathy treatment page describes similar nerve-pain medicines and explains that treatment also depends on the underlying cause.
That standard-care context matters for medical cannabis assessment. A specialist will usually want to know which relevant nerve-pain treatments have been tried, whether they helped, whether side effects were a problem, and whether any options were unsuitable because of other health issues or medicines.
Where NICE NG144 creates the cannabis boundary
NICE NG144 is the main NICE guideline on cannabis-based medicinal products. In the chronic pain section, NICE says not to offer nabilone, dronabinol, THC, or a CBD and THC combination for chronic pain in adults. It also says not to offer CBD for chronic pain outside a clinical trial.
That does not erase patient experience. Some people with nerve pain report benefit from cannabis-based products. It does mean a public patient guide must not convert anecdotes, small studies or clinic experience into a treatment claim.
The careful line is this:
- neuropathic pain can be severe and difficult to treat;
- standard nerve-pain medicines often come before any cannabis discussion;
- NICE does not recommend cannabis-based medicinal products for chronic pain in adults;
- private specialist assessment is individual and source-bound;
- diagnosis alone does not decide access.
Records and previous treatments
For an access discussion, previous treatment history matters. Patients are commonly asked to show that at least two relevant treatments have not worked well enough, caused problems or been unsuitable. For neuropathic pain, those treatments may include nerve-pain medicines, topical treatments, pain-clinic input, physiotherapy, psychological pain support or condition-specific treatment for the underlying cause.
Start with the Summary Care Record from your GP surgery. If it shows the nerve-pain diagnosis or working diagnosis and recent relevant treatments, it may support an early eligibility check. If the SCR does not show enough detail, a clinic may ask for letters from neurology, diabetes care, pain clinic, oncology, orthopaedics or another specialist service.
Useful preparation can include:
- when the pain started and what it feels like;
- the suspected or confirmed cause of the nerve pain;
- previous medicines tried, including side effects or reasons they were unsuitable;
- current prescription medicines, over-the-counter medicines, supplements and any non-prescribed cannabinoid use;
- relevant scans, nerve tests or specialist letters where available;
- mental health history, driving, work safety and previous adverse cannabis reactions.
For records help, see how to request your Summary Care Record and what counts as trying two treatments.
Safety and medicine interactions
Neuropathic pain patients may already be taking medicines that cause drowsiness, dizziness, concentration problems or falls risk. Gabapentinoids, antidepressants used for pain, opioids, sleep medicines, benzodiazepines, antiepileptic medicines and other central-nervous-system medicines all make interaction review more relevant.
The NHS medical cannabis page says CBD and THC can affect how other medicines work. The useful patient action is honesty and preparation, not self-diagnosing interaction risk. Give the prescriber and pharmacist a complete list of medicines, supplements, alcohol use and cannabinoid products.
Safety screening may also cover:
- mental health history, including psychosis, schizophrenia history, bipolar or mania risk, severe depression, suicidality and previous adverse cannabis reactions;
- driving, work safety and impairment if THC is involved;
- liver, kidney, cardiovascular, pregnancy, breastfeeding or substance-use concerns;
- whether the underlying cause of the nerve pain needs separate review or treatment.
Do not stop, switch or reduce existing nerve-pain medicines without clinical advice. If medical cannabis is discussed, it should be part of a specialist review, not a self-directed replacement plan.
What to ask a specialist
Useful questions include:
- Does my pain look neuropathic, mixed or something else?
- Which previous treatments are most relevant to this assessment?
- Does my Summary Care Record show enough, or do you need specialist letters?
- How does NICE NG144 affect a neuropathic pain discussion?
- What interactions matter with my current medicines?
- What side effects, impairment or mental-health risks are most relevant for me?
- How would benefit and side effects be reviewed if treatment were considered?
- What happens if treatment does not help or causes problems?
Patients can ask informed questions about forms such as oil, flower or extract if the consultation reaches that point. The prescriber decides suitability, product, dose, route and monitoring.
FAQ
Does neuropathic pain qualify for medical cannabis in the UK?
Not by diagnosis alone. Neuropathic pain may be part of a specialist assessment, but the decision depends on diagnosis, treatment history, current medicines, risk factors and clinical judgement.
Does NICE recommend medical cannabis for neuropathic pain?
NICE’s cannabis-based medicinal products guideline does not recommend several cannabis-based medicines for chronic pain in adults. NICE’s neuropathic pain guideline focuses on standard nerve-pain medicines and does not create a medical cannabis access route.
What treatments usually matter before a cannabis discussion?
It depends on the cause of the nerve pain, but records often need to show relevant standard treatments tried, not tolerated or unsuitable. Examples can include amitriptyline, duloxetine, gabapentin, pregabalin, topical treatments or specialist pain input.
Is neuropathic pain different from chronic pain generally?
Yes. Neuropathic pain is linked to nerve damage or nervous-system dysfunction. A person can also have mixed pain, where nerve pain overlaps with musculoskeletal, inflammatory or chronic primary pain.
Can this article recommend a product or dose?
No. Product, form, dose, route, monitoring and suitability belong with a specialist prescriber.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NICE. Neuropathic pain in adults: pharmacological management, CG173. https://www.nice.org.uk/guidance/cg173
- NHS. Peripheral neuropathy treatment. https://www.nhs.uk/conditions/peripheral-neuropathy/treatment/
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- CQC. Cannabis-based medicinal products: what CQC expects from providers. https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
Cover image brief: cover-brief.md.
